The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome
The TASC trial represents a significant step forward by being the first phase 3 randomized controlled trial to directly compare therapeutic versus prophylactic-dose tinzaparin for managing acute chest syndrome (ACS) in adults with sickle cell disease who do not have pulmonary artery macrothrombosis. The primary finding was that using therapeutic-dose tinzaparin successfully reduced the overall time required for ACS resolution when compared to standard prophylactic dosing. Furthermore, this higher level of anticoagulation appeared associated with a clinically meaningful reduction in opioid consumption during the acute episode. These results suggest that simply maintaining prophylaxis might not be optimal care for all patients presenting with ACS.
The TASC trial represents a significant step forward by being the first phase 3 randomized controlled trial to directly compare therapeutic versus prophylactic-dose tinzaparin for managing acute chest syndrome (ACS) in adults with sickle cell disease who do not have pulmonary artery macrothrombosis. The primary finding was that using therapeutic-dose tinzaparin successfully reduced the overall time required for ACS resolution when compared to standard prophylactic dosing. Furthermore, this higher level of anticoagulation appeared associated with a clinically meaningful reduction in opioid consumption during the acute episode. These results suggest that simply maintaining prophylaxis might not be optimal care for all patients presenting with ACS.
Show moreShow less
For stable adults with sickle cell disease presenting with ACS without evidence of pulmonary artery macrothrombosis, consider escalating anticoagulation to a therapeutic dose if initial supportive measures fail to rapidly improve the patient. The data suggest this higher dosing may accelerate resolution and reduce opioid burden, but always weigh the increased bleeding risk against these benefits.